Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Users of Provue system for blood screening

Articles with lock require a subscription to GLG News | Request a free trial
August 21, 2007
Impact of restrictions on gifts to MD's on prescribing patterns
Analysis of: NY bill would require pharmas to report MD gifts | www.fiercehealthcare.com
Author: Robert Boorstein, Director of Pathology, Bellevue Hospital Center
Pharmaceutical companies spend over $10,000 per physician on direct gifts and similar activities.  These activities are designed to influence prescribing patterns, and most certainly do.  Monitoring sales of drug classes as drugs come off patent, as in anti allergy medications, drugs for acid...
August 21, 2007
Carrots and sticks to improve patient safety.
Analysis of: By 2008, Medicare won't pay for hospital errors | www.fiercehealthcare.com
Author: Robert Boorstein, Director of Pathology, Bellevue Hospital Center
The last several years as seen the growth of financial incentives to stimulate improvements in patient safety and patient outcomes.  Clearly society has an interest in improving patient safety, and aligning providers and payers financially is a laudable goal. The use of denied payments raises the...
February 28, 2007
Is this the future of laboratory automation
Analysis of: GE to acquire Abbott's invitro and point of care diagnostics businesses | egems.gehealthcare.com
Author: Robert Boorstein, Director of Pathology, Bellevue Hospital Center
How much will Abbott contribute to bottom line of GE.What is future of Abbott.
February 9, 2007
Implications of new breast cancer prognostic methodology
Analysis of: FDA Approves Test | online.wsj.com
Author: Robert Boorstein, Director of Pathology, Bellevue Hospital Center
Approval of the Mammaprint is a significant advance clinically, as it is the first FDA approved gene expression test for breast cancer.  If it is widely accepted, it would represent one of the highest value cancer diagnostic products.  The technology would presumably be extended to other common...
January 23, 2007
Non genetic factors determining warfarin dose
Analysis of: DNA tests to determine warfarin dose | news.yahoo.com
Author: Robert Boorstein, Director of Pathology, Bellevue Hospital Center
Using DNA tests to predict appropriate warfarin dosages clearly has market potential.   However, it is yet to be proven that such testing will significantly reduce the trial and error basis of such, and the article discusses trials that are underway.It should be noted that the causes of underdoses...

Page : 11 to 5 of 5

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-04T13:45:22.160